Recommended by one of our members – Pharmacy2U

We take care of your NHS Repeat Prescriptions. With easy online ordering, free flexible delivery and reminders to re-order.

Get your NHS repeat prescriptions delivered FREE to your door. We arrange and deliver your NHS repeat prescriptions to your door – for free. The Electronic Prescription Service is an NHS service which allows you to manage your repeat prescriptions online. Register today in three easy steps.

Researchers devise AI-based method of detecting response to MS

Source UCLH.nhs.uk: UCLH’s Biomedical Research Centre has supported the development of a new artificial intelligence-based method for detecting the brain’s response to treatment in multiple sclerosis (MS) that is substantially better than what a human expert is able to do using conventional techniques, representing potentially ‘superhuman’ performance in the task.

UCL researchers – led by Dr Parashkev Nachev and Prof Olga Ciccarelli, both of the UCL Institute of Neurology – in partnership with Kings College London researchers, hope in future this method will be used to predict an individual’s response to a drug before they start treatment, and which drug a patient should be given.

One way of assessing MS treatment response is by analysing patients’ MRI scans. At present, radiologists assess scans by counting the number of lesions and measuring lesion volumes, comparing these observations with those made on scans done before treatment started.

But the researchers’ new AI-based method of analysing scans means that regions of the brain can be analysed in much greater detail, and in a way which more closely reflects the complexity of the brain.  Read on. 

Volunteers needed

Volunteers needed to help with our collection at Millets Farm on Saturday 29th June, we have some time slots not covered at all. Please help if you can.

Thank you!

Thank you to those who gave up their time to collect on Sunday (2nd June) at Tesco Abingdon; Angela and John Day, Geoff and Brenda Fewings, Andy and Julia Gower, Dave Webb and Terry Saunders.  A great collection, totalling: £447.66

We have another collection this month on Saturday 29th June at Millets Farm, Frilford, if anyone can help please let me know.

Sue

Good news! NICE approves Ocrevus (ocrelizumab) for primary progressive MS

Source MS Trust: The MS Trust is delighted that Ocrevus (ocrelizumab) has been approved by NICE for NHS treatment of early, inflammatory primary progressive MS.

NICE has approved Ocrevus for people with primary progressive MS if they:

  • have had symptoms of primary progressive MS for 15 years or less and
  • are able to walk 20 metres or more, with or without walking aids (up to EDSS 6.5) and
  • have evidence of MS activity on MRI scans

This reverses an earlier decision by NICE to reject Ocrevus for PPMS. The final publication of this decision was paused to allow time for further discussions to take place between NICE, NHS England and drug manufacturer Roche.  Read on.

Multiple Sclerosis News Today Daily Digest

Worth reading, the Ocrelizumab (Ocrevus) story, plus second and third items.  But a warning to all, not all the comments are positive.

Multiple Sclerosis News Today

The Web’s Daily Resource for Multiple Sclerosis News

In the 05/13/2019 edition:

Excerpts:MS News that Caught My Eye Last Week: Lemtrada Satisfaction, Limiting Tysabri’s PML Risk, MS and Pregnancy, Infusions Vs. Pills#AANAM – RRMS Patients Switching to Lemtrada Report Greater Satisfaction with Treatment and Improvements in Quality of Life I’m a self-proclaimed secondary progressive, rather than a remitting, multiple sclerosis (MS) person. But a year after round two of Lemtrada (alemtuzumab), I can agree with this report. Several of my symptoms are better, most notably my […]The post MS News that Caught My Eye Last Week: Lemtrada Satisfaction, Limiting Tysabri’s PML Risk, MS and Pregnancy, Infusions Vs. Pills appeared first on Multiple Sclerosis News Today.
Read on »

Ocrevus Approved in UK as First NHS Treatment for PPMSAfter first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now approved the use of Ocrevus (ocrelizumab) for people in the U.K. with early, inflammatory primary progressive multiple sclerosis (PPMS). This means that PPMS patients living in the U.K. will now have access to Ocrevus treatment through the […]The post Ocrevus Approved in UK as First NHS Treatment for PPMS appeared first on Multiple Sclerosis News Today.
Read on »

#AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data SuggestEarly, one-year data from the Phase 3 CHORDS study show that Ocrevus effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying therapies. These interim results were presented at the 2019 annual meeting of the American Academy of Neurology (AAN) in the presentation, “One-year interim analysis results of the […]The post #AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest appeared first on Multiple Sclerosis News Today.
Read on »

#AANAM – Aubagio at Higher Dose Shows Long-term Efficacy in Variety of Patients, Trial Data ShowAubagio taken as 14 milligram (mg) tablet once daily significantly reduces the risk of relapse in people with relapsing multiple sclerosis (MS) over time irrespective of their prior treatment history, a pooled analysis of Phase 2 and Phase 3 trial results show. The findings were presented at the 2019 American Academy of Neurology (AAN) Annual Meeting, […]The post #AANAM – Aubagio at Higher Dose Shows Long-term Efficacy in Variety of Patients, Trial Data Show appeared first on Multiple Sclerosis News Today.
Read on »

I Survived a Marathon Comedy FestivalExactly one year ago on this day of writing, I was down and out. This year, I’m not exactly fighting fit, but the same set of circumstances has pushed me the distance. But it didn’t floor me. OK, OK, I’ll stop with the pugilistic metaphors — it’s not exactly knocking you out! Last year, I […]The post I Survived a Marathon Comedy Festival appeared first on Multiple Sclerosis News Today.
Read on »

#AANAM – Interferon Beta Exposure Does Not Seem to Increase Risk of Pregnancy Complications, Study SuggestsExposure to interferon beta does not seem to increase the risk of complications during pregnancy in women with multiple sclerosis (MS), new research suggests. The data were presented in an oral presentation, “Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and MS Preg study conducted in Finland and […]The post #AANAM – Interferon Beta Exposure Does Not Seem to Increase Risk of Pregnancy Complications, Study Suggests appeared first on Multiple Sclerosis News Today.
Read on »


General Meeting 13th June 2019

Notice of General Meeting

Notice is hereby given that a General Meeting (Meeting) of The M.S. Therapy Centre (Oxford) Ltd (Company) will be held at 37e, Innovation Drive, Milton Park, Abingdon, OX14 4RT on June 13th2019 at noon.

You will be asked to consider and vote on the resolution below. The resolution will be proposed as a special resolution.

SPECIAL RESOLUTION

THAT the articles of association in the form tabled at the meeting be and are hereby adopted as the articles of association of the Company in substitution for and to the exclusion of all other articles of association.

A copy of the Articles is attached to this notice.

By order of the Board

Andrew John Gower

Director

Registered Office

37e, Innovation Drive

Milton Park

Abingdon

OX14 4RT

Registered number: 2318549

May 13th2019

Notes to the Notice of General Meeting

If any member wishes to appoint a proxy, or wishes to receive an electronic copy of the articles before the meeting, please contact the chairman at andrewgower8@gmail.com.